Resource Type

Journal Article 38

Year

2024 1

2023 5

2022 4

2021 4

2020 6

2019 8

2018 1

2016 2

2014 1

2013 2

2010 1

2009 1

1999 1

open ︾

Keywords

immunotherapy 4

cancer immunotherapy 3

Chimeric antigen receptor 2

Efficacy 2

T cell 2

chimeric antigen receptor T cell 2

cytokine release syndrome 2

hematopoietic stem cell transplantation 2

3D printing 1

Brucella melitensis 1

Salmonella 1

Alloimmunity 1

Angiogenesis 1

Antibody purification 1

Antibody–drug conjugate 1

Antigen 1

Antigen testing 1

Antigen-binding fragment 1

Autoimmunity 1

open ︾

Search scope:

排序： Display mode:

Chimeric antigen receptor T cell therapies for acute myeloid leukemia

Bin Gu, Jianhong Chu, Depei Wu

Frontiers of Medicine 2020, Volume 14, Issue 6,   Pages 701-710 doi: 10.1007/s11684-020-0763-z

Abstract: Abstract Chimeric antigen receptor T cell (CAR T) therapies have achieved unprecedented efficacy in B-cellAlthough the identification of an ideal target antigen for AML is challenging, CAR T therapy remains

Keywords： acute myeloid leukemia     CAR T     immunotherapy    

HTML PDF Collect

Advancement of human leukocyte antigen-partially matched related hematopoietic stem cell transplantation

Xiaodong Mo, Xiaojun Huang

Frontiers of Medicine 2013, Volume 7, Issue 3,   Pages 306-315 doi: 10.1007/s11684-013-0279-x

Abstract: transplantation (HSCT) is one of the most effective options for hematological malignancies, and human leukocyte antigen-partially+positive selection and CD3/CD19 depletion has successfully overcome the human leukocyte antigen

Keywords： partially matched related donor     hematopoietic stem cell transplantation     allogeneic    

HTML PDF Collect

A giant step forward: chimeric antigen receptor T-cell therapy for lymphoma

Houli Zhao, Yiyun Wang, Elaine Tan Su Yin, Kui Zhao, Yongxian Hu, He Huang

Frontiers of Medicine 2020, Volume 14, Issue 6,   Pages 711-725 doi: 10.1007/s11684-020-0808-3

Abstract: Chimeric antigen receptor T (CAR-T) cells were introduced as a treatment for these patients.

Keywords： chimeric antigen receptor T (CAR-T) cell     lymphoma     cytokine release syndrome (CRS)     immune effector cell-associated    

HTML PDF Collect

Serum carbohydrate antigen (CA) 19-9 as a prognostic factor in cholangiocarcinoma: A meta-analysis

Shang-Long LIU, Zi-Fang SONG, Qing-Gang HU, Shao-Bo HU, Jun LI, Qi-Chang ZHENG, Duo SHAN,

Frontiers of Medicine 2010, Volume 4, Issue 4,   Pages 457-462 doi: 10.1007/s11684-010-0240-1

Abstract: This study was performed to determine the prognostic role of preoperative serum carbohydrate antigen

Keywords： cholangiocarcinoma     prognostic factors     serum carbohydrate antigen 19-9    

HTML PDF Collect

CAR T cells redirected against tumor-specific antigen glycoforms: can low-sugar antigens guarantee a

Frontiers of Medicine 2022, Volume 16, Issue 3,   Pages 322-338 doi: 10.1007/s11684-021-0901-2

Abstract: To date, six chimeric antigen receptor T cell (CAR-T) therapies have been permitted for the treatment

Keywords： cancer immunotherapy     chimeric antigen receptor     solid tumors     tumor-associated antigen     glycosylation    

HTML PDF Collect

Detection and monitoring prostate specific antigen using nanotechnology approaches to biosensing

Grant Perry, Fernando Cortezon-Tamarit, Sofia I. Pascu

Frontiers of Chemical Science and Engineering 2020, Volume 14, Issue 1,   Pages 4-18 doi: 10.1007/s11705-019-1846-8

Abstract: The detection of the prostate specific antigen (PSA) in blood samples has been the preferred method for

Keywords： biosensing     immunosensor     PSA     prostate cancer     fluorescence    

HTML PDF Collect

may affect the survival of patients with relapsed or refractory non-Hodgkin lymphoma after chimeric antigen

Lili Zhou, Ping Li, Shiguang Ye, Xiaochen Tang, Junbang Wang, Jie Liu, Aibin Liang

Frontiers of Medicine 2020, Volume 14, Issue 6,   Pages 786-791 doi: 10.1007/s11684-020-0751-3

Abstract: Factors associated with complete and durable remissions after anti-CD19 chimeric antigen receptor T (

Keywords： anti-CD19 chimeric antigen receptor T cell     soft tissue     bone marrow     relapsed or refractory non-Hodgkin    

HTML PDF Collect

Chimeric antigen receptor T cell targeting EGFRvIII for metastatic lung cancer therapy

Zhao Zhang, Jun Jiang, Xiaodong Wu, Mengyao Zhang, Dan Luo, Renyu Zhang, Shiyou Li, Youwen He, Huijie Bian, Zhinan Chen

Frontiers of Medicine 2019, Volume 13, Issue 1,   Pages 57-68 doi: 10.1007/s11684-019-0683-y

Abstract: In recent years, the development of tumor immunotherapy especially chimeric antigen receptor T (CAR-TThus, EGFRvIII is a potential antigen for targeted lung cancer therapy.The proliferation of CAR-T cells were induced by cytokine and specific antigen in vitro.

Keywords： chimeric antigen receptor T cells     epidermal growth factor receptor     lung cancer     immunotherapy     tumor immunolog    

HTML PDF Collect

Phase I study of CBM.CD19 chimeric antigen receptor T cell in the treatment of refractory diffuse large

Frontiers of Medicine 2022, Volume 16, Issue 2,   Pages 285-294 doi: 10.1007/s11684-021-0843-8

Abstract: Anti-CD19 chimeric antigen receptor (CAR) T cell therapy has shown impressive efficacy in treating B-cell

Keywords： CAR-T cell therapy     refractory diffuse large B-cell lymphoma     cytokine release syndrome     dose-limiting toxicity    

HTML PDF Collect

Chimeric antigen receptor T-cell therapy: a promising treatment modality for relapsed/refractory mantle

Ping Li, Ningxin Dong, Yu Zeng, Jie Liu, Xiaochen Tang, Junbang Wang, Wenjun Zhang, Shiguang Ye, Lili Zhou, Alex Hongsheng Chang, Aibin Liang

Frontiers of Medicine 2020, Volume 14, Issue 6,   Pages 811-815 doi: 10.1007/s11684-020-0740-6

Abstract: Chimeric antigen receptor (CAR) T-cell therapy has emerged as a novel treatment modality for r/r non-Hodgkin

Keywords： anti-CD19 chimeric antigen receptor T cells     mantle cell lymphoma     relapsed or refractory     long-term follow-up    

HTML PDF Collect

Tumor-derived exosomes induce initial activation by exosomal CD19 antigen but impair the function of

Frontiers of Medicine doi: 10.1007/s11684-023-1010-1

Abstract: Tumor-derived exosomes induce initial activation by exosomal CD19 antigen but impair the function of

Keywords： exosomes induce activation     impair function CD19     exosomal CD19 antigen    

HTML PDF Collect

microenvironment contributes to tumor progression in diffuse large B-cell lymphoma upon anti-CD19 chimeric antigen

Frontiers of Medicine 2023, Volume 17, Issue 4,   Pages 699-713 doi: 10.1007/s11684-022-0972-8

Abstract: Anti-CD19 chimeric antigen receptor (CAR)-T cell therapy has achieved 40%–50

Keywords： anti-CD19 chimeric antigen receptor T     immunotherapy     diffuse large B cell lymphoma     tumor microenvironment    

HTML PDF Collect

Pandemic Woes: Antigen Tests to the Rescue?

Peter Weiss

Engineering 2021, Volume 7, Issue 1,   Pages 3-5 doi: 10.1016/j.eng.2020.12.002

HTML PDF Collect

between event-free patients receiving haploidentical allografts and those receiving human leukocyte antigen-matched

Xuying Pei, Xiangyu Zhao, Yu Wang, Lanping Xu, Xiaohui Zhang, Kaiyan Liu, Yingjun Chang, Xiaojun Huang

Frontiers of Medicine 2018, Volume 12, Issue 2,   Pages 153-163 doi: 10.1007/s11684-017-0548-1

Abstract:

To establish optimal reference values for recovered immune cell subsets, we prospectively investigated post-transplant immune reconstitution (IR) in 144 patients who received allogeneic stem cell transplantation (allo-SCT) and without showing any of the following events: poor graft function, grades II?IV acute graft-versus-host disease (GVHD), serious chronic GVHD, serious bacterial infection, invasive fungal infection, or relapse or death in the first year after transplantation. IR was rapid in monocytes, intermediate in lymphocytes, CD3+ T cells, CD8+ T cells, and CD19+ B cells, and very slow in CD4+ T cells in the entire patient cohort. Immune recovery was generally faster under HLA-matched sibling donor transplantation than under haploidentical transplantation. Results suggest that patients with an IR comparable to the reference values display superior survival, and the levels of recovery in immune cells need not reach those in healthy donor in the first year after transplantation. We suggest that data from this recipient cohort should be used as reference values for post-transplant immune cell counts in patients receiving HSCT.

Keywords： immune reconstitution     hematopoietic stem cell transplantation     event-free patients     reference range    

HTML PDF Collect

Radial porous SiO

Chuangnian Zhang, Ying Dong, Jing Gao, Xiaoli Wang, Yanjun Jiang

Frontiers of Chemical Science and Engineering 2021, Volume 15, Issue 5,   Pages 1296-1311 doi: 10.1007/s11705-020-2034-6

Abstract: The antigen ovalbumin was covalently conjugated onto the as-synthesized hierarchical SiO nanoflowersThe nanovaccine exhibited excellent storage stability without antigen release after 27 days of incubation, negligible cytotoxicity to dendritic cells, and a high antigen loading capacity of 430±66 mg·g supportAnd the enhancement of antigen/adjuvant uptake and lysosome escape of antigen were observed.marrow-derived dendritic cells in the presence of nanovaccine proved the activation of dendritic cells and antigen

Keywords： silica nanoflower     antigen delivery     cancer immunotherapy     nanovaccine    

HTML PDF Collect

Title Author Date Type Operation

Chimeric antigen receptor T cell therapies for acute myeloid leukemia

Bin Gu, Jianhong Chu, Depei Wu

Journal Article

Advancement of human leukocyte antigen-partially matched related hematopoietic stem cell transplantation

Xiaodong Mo, Xiaojun Huang

Journal Article

A giant step forward: chimeric antigen receptor T-cell therapy for lymphoma

Houli Zhao, Yiyun Wang, Elaine Tan Su Yin, Kui Zhao, Yongxian Hu, He Huang

Journal Article

Serum carbohydrate antigen (CA) 19-9 as a prognostic factor in cholangiocarcinoma: A meta-analysis

Shang-Long LIU, Zi-Fang SONG, Qing-Gang HU, Shao-Bo HU, Jun LI, Qi-Chang ZHENG, Duo SHAN,

Journal Article

CAR T cells redirected against tumor-specific antigen glycoforms: can low-sugar antigens guarantee a

Journal Article

Detection and monitoring prostate specific antigen using nanotechnology approaches to biosensing

Grant Perry, Fernando Cortezon-Tamarit, Sofia I. Pascu

Journal Article

may affect the survival of patients with relapsed or refractory non-Hodgkin lymphoma after chimeric antigen

Lili Zhou, Ping Li, Shiguang Ye, Xiaochen Tang, Junbang Wang, Jie Liu, Aibin Liang

Journal Article

Chimeric antigen receptor T cell targeting EGFRvIII for metastatic lung cancer therapy

Zhao Zhang, Jun Jiang, Xiaodong Wu, Mengyao Zhang, Dan Luo, Renyu Zhang, Shiyou Li, Youwen He, Huijie Bian, Zhinan Chen

Journal Article

Phase I study of CBM.CD19 chimeric antigen receptor T cell in the treatment of refractory diffuse large

Journal Article

Chimeric antigen receptor T-cell therapy: a promising treatment modality for relapsed/refractory mantle

Ping Li, Ningxin Dong, Yu Zeng, Jie Liu, Xiaochen Tang, Junbang Wang, Wenjun Zhang, Shiguang Ye, Lili Zhou, Alex Hongsheng Chang, Aibin Liang

Journal Article

Tumor-derived exosomes induce initial activation by exosomal CD19 antigen but impair the function of

Journal Article

microenvironment contributes to tumor progression in diffuse large B-cell lymphoma upon anti-CD19 chimeric antigen

Journal Article

Pandemic Woes: Antigen Tests to the Rescue?

Peter Weiss

Journal Article

between event-free patients receiving haploidentical allografts and those receiving human leukocyte antigen-matched

Xuying Pei, Xiangyu Zhao, Yu Wang, Lanping Xu, Xiaohui Zhang, Kaiyan Liu, Yingjun Chang, Xiaojun Huang

Journal Article

Radial porous SiO

Chuangnian Zhang, Ying Dong, Jing Gao, Xiaoli Wang, Yanjun Jiang

Journal Article